As part of AppliedClinicalTrial's deep dive into #AI 's impact, Stephen Pyke examined why data sharing is critical for refining generative AI models like ChatGPT. Hear why “fine tuning” is needed to advance these applications and why collaboration is key to fulfilling the promise of AI:

In this article, Ola Lubojemska and Andreas Lysandropoulos offer valuable insights on differentiating new #neuroscience drugs in crowded markets and the anticipatory steps to take, ensuring optimal go-to-market outcomes. #MarketAccess #Regulatory #ParexelBiotech

Ukraine has faced significant challenges due to the war but Parexel has remained committed to supporting our clinical operations throughout the crisis. In PharmaVoice, Deb Tatton and Aleksei Zhmuro share how the company has ensured research continuity and access to trials:

📹In the final part of this video interview with ACT editor Andy Studna, Stephen Pyke, chief clinical data and digital officer, Parexel, highlights the importance of human oversight when using artificial intelligence to aid in decision making
appliedclinicaltrialsonline.com/view/the-role-…

In Part 2 of his AppliedClinicalTrial interview, Stephen Pyke reveals areas where we might see major advancements in our industry due to #AI . Integrating AI could drive speed, quality and productivity in clinical research, leading to transformative impact on patient outcomes. Watch here:

Join us to hear perspectives from top clinical research experts and disease area specialists on the similarities and differences in Alzheimer’s Disease (AD) and Multiple Sclerosis (MS) treatments. 🧠

Parexel is looking for #Regulatory Consultants! We're focused on advancing the future of healthcare while keeping the patient at the heart of everything we do. Help us bring forward therapies that could change patient lives. Apply today:
#ClinicalResearch #CRO #ClinicalTrials

CPHI 2024 Pharma Outsourcing Forecast reveals insights on outsourcing and how sponsor, CRO and vendor partnerships impact supply chain efficiency. Our #FSP experts Neil Berger and Kerri McCaul-Claus discuss collaboration through shared-risk outsourcing partnership models.

Our team is heading to Denver this weekend for the largest annual meeting of neurologists and neuroscience professionals, #AANAM 2024! Stop by booth 997 to connect with Andreas Lysandropoulos, SVP and Global Therapeutic Area Head - Neuroscience at Parexel.

In Part 1 of this series, Stephen Pyke joins AppliedClinicalTrial to discuss the impact of #AI on clinical trials. In 2021 a shocking 132 submissions to the FDA included some aspect of AI, yet Stephen cautions there's still a long road ahead for widespread adoption. Learn why:

Join experts Anne Kasmar and Leslie Johnston, as they share their thoughts on the fast pace required to test novel #Vaccines in large representative trials, lessons learned from the COVID pandemic, and best practices to enable efficiency.

🗓️ Date: 04/18/24 ⏰ Time: 11:00 am EST

Following our recognition as the 'Best CRO' from @Scrip we asked our colleagues' opinion on why we won. To Dr. Amy McKee, the award symbolizes our #PatientsFirst focus and our commitment to always bringing patient and care partner perspectives to the table.

Meet Vivek, Senior Manager, Statistical Programming, who leads a local team of more than 18 programmers. Learn where he finds joy in his work ─ from continuous learning opportunities to the collaborative environment ─ and check out photos from recent events at Parexel Mumbai.

'No matter how innovative the science, no matter how well designed the study — if payers won’t agree to reimburse the cost of a therapy, patients will never benefit from it.'

In our latest New Medicines, #NovelInsights newsletter, we share why patient insights are essential.

Gain firsthand experience from Parexel's regulatory experts who have made over 250 EU-CTR applications, including almost 50 transition submissions. 📋 Our EU-CTR readiness can support you in navigating the requirements of this regulatory process successfully. #EUCTR #CTIS

This year's #WorldHealthDay theme champions everyone's right to healthcare, yet many patients are underrepresented in clinical research. This research paper by Duke-Margolis, partly informed by Parexel's experts, explores how RWD/E can address such healthcare disparities.

Members of Parexel’s Statistical Programming group analyze clinical data from a variety of therapeutic areas while working closely with sponsors and internal teams ─ and in an environment that fosters growth! Sound like you? Help us bring treatments to patients faster:

Parexel's David Barrett breaks down the shortcomings of typical RWD in clinical research and offers a new study protocol leveraging secure tokenization to better link patient characteristics with RWD.